Anti-TNFRSF4 Antibody, clone 3N2 ZooMAb^® Rabbit Monoclonal

Tumor necrosis factor receptor superfamily member 4 (UniProt: P43489; also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD134) is encoded by the TNFRSF4 (also known as TXGP1L) gene (Gene ID: 7293) in human. TNFRSF4 is a member of the tumor necrosis factor receptor superfamily primarily expressed on activated T cells and regulatory T cells. It is a single-pass type I transmembrane protein with extracellular cysteine-rich domains that enable ligand binding. Its primary ligand, TNFSF4 (OX40L), is expressed on antigen-presenting cells, facilitating immune activation and T-cell survival. TNFRSF4 signaling is mediated through interactions with adaptor proteins TRAF2, TRAF3, and TRAF5, which activate downstream pathways such as NF-kB and MAPK, leading to enhanced cytokine production and T-cell proliferation. TNFRSF4 is upregulated in various cancers, including hepatocellular carcinoma (HCC), lung cancer, and breast cancer, where it correlates with immune cell infiltration and tumor progression. Elevated TNFRSF4 expression is associated with poor prognosis in HCC, as it promotes T-cell exhaustion and epithelial-mesenchymal transition (EMT) pathways, leading to immune evasion and aggressive tumor phenotypes. Additionally, TNFRSF4 has been implicated in autoimmune diseases, such as systemic lupus erythematosus (SLE), where it is involved in dysregulated B-cell and interferon signaling pathways. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

KLH-conjugated linear peptide corresponding to 22 amino acids from the C-terminal extracellular domain of human TNFRSF4.

Quality Control Testing

Evaluated by Western Blotting in lysate from human peripheral blood mononuclear cells (PBMC) treated with phytohaemagglutinin.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected TNFRSF4 in lysate from human peripheral blood mononuclear cells (PBMC) treated with phytohaemagglutinin (PHA: 10 g/mL; 2 days).

Tested Applications

Affinity Binding Assay: A representative lot of this antibody bound with TNFRSF4 peptide with at least ten thousand-fold (10,000X) higher affinity than with non-specific control peptide.

ELISA: A representative lot of this antibody detected TNFRSF4 protein in ELISA application.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected TNFRSF4 in MOLT-4 cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 3N2 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects TNFRSF4. It targets an epitope within 22 amino acids from the C-terminal extracellular domain.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.